<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383785</url>
  </required_header>
  <id_info>
    <org_study_id>PI-2008/52</org_study_id>
    <nct_id>NCT01383785</nct_id>
  </id_info>
  <brief_title>Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab</brief_title>
  <acronym>TOLEDO1</acronym>
  <official_title>Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Virgen de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Virgen de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims: (to prove that) The distal injection of IIb IIIa platelet receptor blocker to the
      thrombus occlusion is better than normal injection during primary percutaneous intervention
      (PCI) for the treatment of acute myocardial infarction. Using this modification of injection
      method the investigators can achieve less microvascular damage and a reduction of the infarct
      size with a significant improvement of the outcome at six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are some evidence about the utilization of aspiration catheter (Indication class IIb
      with level of evidence B in European Guidelines) and intravenous abciximab (indication Class
      IIa an level of evidence A in European Guidelines) in primary PTCA. Direct intracoronary
      injection of abciximab get smaller infarct size than intravenous injection. The hypothesis of
      our study are that direct distal injection of abciximab by aspiration catheter will be better
      than proximal intracoronary injection with reduction in infarct size and microvascular damage
      quantified by Magnetic resonance (MR) and 6 months mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size</measure>
    <time_frame>Between 2 and 9 days after primary ptca</time_frame>
    <description>Infarct size quantified by MR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Events (MACCE)</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac mortality, reinfarction, new revascularization, and stroke</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Occlusive Thrombus</condition>
  <arm_group>
    <arm_group_label>GROUP A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary full bolus dose of abciximab proximal to thrombus occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary direct injection</intervention_name>
    <description>Abciximab bolus dosage: 0,125 mg/kg.
Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory.</description>
    <arm_group_label>GROUP A</arm_group_label>
    <other_name>Abciximab, thrombus aspiration catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary and distal injection by aspiration device</intervention_name>
    <description>Abciximab bolus dosage: 0,125 mg/kg.
Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C.</description>
    <arm_group_label>GROUP B</arm_group_label>
    <other_name>Abciximab, thrombus aspiration catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary distal injection by aspiration catheter device</intervention_name>
    <description>Abciximab bolus dosage: 0,125 mg/kg.
Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter.</description>
    <arm_group_label>GROUP C</arm_group_label>
    <other_name>Abciximab, thrombus aspiration catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myocardial infarction patients between 3 and 12 hours after symptoms onset

        Exclusion Criteria:

          -  Hemodynamic instability

          -  TIMI flow 2 or 3

          -  Life expectance less than 6 months

          -  Contraindication to AAS, clopidogrel or abciximab

          -  Severe tortuosity of occluded vessel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Moreu, Phd,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Salud. Toledo. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Rodriguez-Padial, Phd MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Virgen de la Salud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Moreu, MD,PhD</last_name>
    <phone>+34 925 269 188</phone>
    <email>jmoreu@sescam.jccm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Pajin, MD</last_name>
    <phone>+34 925 269 188</phone>
    <email>lfpajinv@sescam.jccm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Moreu, pHD,md</last_name>
      <phone>+34 925 269 188</phone>
      <email>jmoreu@sescam.jccm.es</email>
    </contact>
    <investigator>
      <last_name>Tomas Canton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Pajin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Lazaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Nu√±ez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belen Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Garcia de Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramon Barciela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12.</citation>
    <PMID>19004841</PMID>
  </reference>
  <reference>
    <citation>Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008 Feb 7;358(6):557-67. doi: 10.1056/NEJMoa0706416.</citation>
    <PMID>18256391</PMID>
  </reference>
  <reference>
    <citation>Vetrovec GW. Improving reperfusion in patients with myocardial infarction. N Engl J Med. 2008 Feb 7;358(6):634-7. doi: 10.1056/NEJMe0708910.</citation>
    <PMID>18256399</PMID>
  </reference>
  <reference>
    <citation>Thiele H, Schindler K, Friedenberger J, Eitel I, F√ºrnau G, Grebe E, Erbs S, Linke A, M√∂bius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.</citation>
    <PMID>18559698</PMID>
  </reference>
  <reference>
    <citation>Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008 Jul 15;52(3):181-9. doi: 10.1016/j.jacc.2008.04.006.</citation>
    <PMID>18617066</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>February 20, 2012</last_update_submitted>
  <last_update_submitted_qc>February 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Virgen de la Salud</investigator_affiliation>
    <investigator_full_name>J.Moreu</investigator_full_name>
    <investigator_title>Director catheterization laboratory</investigator_title>
  </responsible_party>
  <keyword>Primary PTCA</keyword>
  <keyword>Thrombus Aspiration Catheter</keyword>
  <keyword>Intracoronary Abciximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

